Pure Biologics

Pure Biologics Debt

The Debt of Pure Biologics (PUR.WA) as of Oct 9, 2026 is 16.01 M PLN. In the previous year, Debt was 14.06 M PLN — a change of 13.85% (higher).

Debt

16.01 MPLN

YoY

13.85%

Last updated:

In 2025, Pure Biologics's total debt was 16.01 M PLN, a 13.85% change from the 14.06 M PLN total debt recorded in the previous year.

The Pure Biologics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
93,835.00 PLN
Jan 1, 2019
5.37 M PLN
Jan 1, 2020
5.01 M PLN
Jan 1, 2021
3.11 M PLN
Jan 1, 2022
2.86 M PLN
Jan 1, 2023
12.94 M PLN
Jan 1, 2024
14.06 M PLN
Jan 1, 2025
16.01 M PLN
The Pure Biologics Debt history
YEARDebtYoY
16.01 MPLN+13.85%
14.06 MPLN+8.66%
12.94 MPLN+352.22%
2.86 MPLN-8.10%
3.11 MPLN-37.80%
5.01 MPLN-6.85%
5.37 MPLN+5,626.01%
93,835.00PLN-39.46%
154,997.00PLN—
Access this data via the Eulerpool API
Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics is one of the most popular companies on Eulerpool.

Debt Details

Understanding Pure Biologics's Debt Structure

Pure Biologics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pure Biologics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pure Biologics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pure Biologics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pure Biologics stock

Debt of Pure Biologics is 16.01 M PLN in 2025.

Debt of Pure Biologics changed from 14.06 M PLN to 16.01 M PLN, representing a 13.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Pure Biologics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Pure Biologics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pure Biologics